This database contains 74 studies, archived under the term: "pathology"
Click here to filter this large number of results.
A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment
Suzuki, Takao,
Shimada, Hiroyuki,
Makizako, Hyuma,
Doi, Takehiko,
Yoshida, Daisuke,
Ito, Kengo,
Shimokata, Hiroshi,
Washimi, Yukihiko,
Endo, Hidetoshi,
Kato, Takashi
Background: To examine the effect of multicomponent exercise program on memory function in older adults with mild cognitive impairment (MCI), and identify biomarkers associated with improvement of cognitive functions.; Methodology/principal Findings: Subjects were 100 older adults (mean age, 75 years) with MCI. The subjects were classified to an amnestic MCI group (n = 50) with neuroimaging measures, […]
The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene
Snowden, Julie S.,
Hu, Quan,
Rollinson, Sara,
Halliwell, Nicola,
Robinson, Andrew,
Davidson, Yvonne S.,
Momeni, Parastoo,
Baborie, Atik,
Griffiths, Timothy D.,
Jaros, Evelyn,
Perry, Robert H.,
Richardson, Anna,
Pickering-Brown, Stuart M.,
Neary, David,
Mann, David M. A.
Frontotemporal lobar degeneration (FTLD) is clinically, pathologically and genetically heterogeneous. Recent descriptions of a pathological sub-type that is ubiquitin positive, TDP-43 negative and immunostains positive for the Fused in Sarcoma protein (FUS) raises the question whether it is associated with a distinct clinical phenotype identifiable on clinical grounds, and whether mutations in the Fused in […]
Alzheimer’s disease (AD) and executive dysfunction. A case-control study on the significance of frontal white matter changes detected by diffusion tensor imaging (DTI)
Sjöbeck, Martin,
Elfgren, Christina,
Larsson, Elna-Marie,
Brockstedt, Sara,
Lätt, Jimmy,
Englund, Elisabet,
Passant, Ulla
White matter (WM) changes are frequently seen on structural imaging in AD but the clinical relevance of these changes is uncertain. Frontal WM pathology is often observed upon neuropathological examination in AD. Since frontal cortical/sub-cortical pathology is known to relate to executive dysfunction, the aim was to elucidate if frontal WM changes in AD correlated […]
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease
Salloway, Stephen,
Sperling, Reisa,
Fox, Nick C.,
Blennow, Kaj,
Klunk, William,
Raskind, Murray,
Sabbagh, Marwan,
Honig, Lawrence S.,
Porsteinsson, Anton P.,
Ferris, Steven,
Reichert, Marcel,
Ketter, Nzeera,
Nejadnik, Bijan,
Guenzler, Volkmar,
Miloslavsky, Maja,
Wang, Daniel,
Lu, Yuan,
Lull, Julia,
Tudor, Iulia Cristina,
Liu, Enchi,
Grundman, Michael,
Yuen, Eric,
Black, Ronald,
Brashear, H. Robert
Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease.; Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease–one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying […]
The effect of midlife physical activity on structural brain changes in the elderly
Rovio, Suvi,
Spulber, Gabriela,
Nieminen, Lasse J.,
Niskanen, Eini,
Winblad, Bengt,
Tuomilehto, Jaakko,
Nissinen, Aulikki,
Soininen, Hilkka,
Kivipelto, Miia
Physical activity has been associated with decreased dementia risk in recent studies, but the effects for structural brain changes (i.e. white matter lesions (WML) and/or brain atrophy) have remained unclear. The CAIDE participants were a random population-based sample studied in midlife and re-examined on average 21 years later (n=2000). A subpopulation (n=75; 31 control, 23 […]
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Rosas, H. D.,
Doros, G.,
Gevorkian, S.,
Malarick, K.,
Reuter, M.,
Coutu, J.-P.,
Triggs, T. D.,
Wilkens, P. J.,
Matson, W.,
Salat, D. H.,
Hersch, S. M.
Objective: To assess the safety and tolerability of high-dose creatine, the feasibility of enrolling premanifest and 50% at-risk subjects in a prevention trial, and the potential of cognitive, imaging, and blood markers.; Methods: Sixty-four eligible consenting participants were randomly allocated (1:1) to 15 g twice daily of creatine monohydrate or placebo for a 6-month double-blind […]
Prospective flutemetamol positron emission tomography and histopathology in normal pressure hydrocephalus
Rinne, Juha O.,
Frantzen, Janek,
Leinonen, Ville,
Lonnrot, Kimmo,
Laakso, Aki,
Virtanen, Kirsi A.,
Solin, Olof,
Kotkansalo, Anna,
Koivisto, Anne,
Sajanti, Juha,
Karppinen, Atte,
Lehto, Hanna,
Rummukainen, Jaana,
Buckley, Chris,
Smith, Adrian,
Jones, Paul A.,
Sherwin, Paul,
Farrar, Gill,
McLain, Richard,
Kailajarvi, Marita,
Grachev, Igor D.
Unlabelled: BACKGOUND/OBJECTIVE: To determine the level of association between uptake of the amyloid positron emission tomography (PET) imaging agent [(18)F]flutemetamol and the level of amyloid-β measured by immunohistochemical and histochemical staining in a frontal cortical region biopsy site.; Methods: Seventeen patients with probable normal pressure hydrocephalus (NPH) underwent prospective [(18)F]flutemetamol PET and subsequent frontal cortical […]
Accelerated cognitive decline in patients with type 2 diabetes: MRI correlates and risk factors
Reijmer, Yael D.,
van den Berg, Esther,
de Bresser, Jeroen,
Kessels, Roy P. C.,
Kappelle, L. Jaap,
Algra, Ale,
Biessels, Geert Jan
Background: Type 2 diabetes mellitus is associated with an increased risk of cognitive decline and dementia. We examined brain imaging correlates and vascular and metabolic risk factors of accelerated cognitive decline in patients with type 2 diabetes.; Methods: Cognitive functioning and brain volume as well as metabolic and vascular risk factors were assessed twice in […]